Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company's product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts.
| Revenue (Most Recent Fiscal Year) | $36.56M |
| Net Income (Most Recent Fiscal Year) | $-88.98M |
| PE Ratio (Current Year Earnings Estimate) | 65.90 |
| PE Ratio (Trailing 12 Months) | 23.26 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.42 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.22 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 26.90% |
| Net Margin (Trailing 12 Months) | 26.25% |
| Return on Equity (Trailing 12 Months) | 18.32% |
| Return on Assets (Trailing 12 Months) | 15.48% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.98 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.98 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.11 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.40 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.65 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.85 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 54.80M |
| Free Float | 49.59M |
| Market Capitalization | $1.08B |
| Average Volume (Last 20 Days) | 0.93M |
| Beta (Past 60 Months) | 1.15 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.50% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |